Emerging Drug Developer


The business case for Cytochroma is built around the shortcomings of two lead therapies for hyperparathyroidism in patients with chronic kidney disease; Hectorol and Zemplar. 

"These two products properly control hyperparathyroidism in 10 percent of treated patients," says Cytochroma CEO Charles Bishop, PhD. "There's an enormous opportunity for better therapies for the disorder." 

Bishop is in a good position to know. He was a senior manager at Bone Care and helped get the NDA approval for Hectorol. Later, he co-founded Proventiv Therapeutics, which was sold to Cytochroma two years ago--a deal which provided two of its top three development programs. And Cytochroma is now moving into a critical phase, providing the data to prove the biotech is on the right path to better treatments. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.